VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ — RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry Significant events in the third quarter of 2025 Received positive feedback from the FDA on the final […]
Tag: Implantica
Implantica presents the third quarter 2025 on October 31 at 15:00 CET
VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ — Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report for the third quarter will be […]
Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™
VADUZ, Liechtenstein, Feb. 12, 2025 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a […]
Implantica publishes Interim Report January
VADUZ, Liechtenstein, Nov. 15, 2024 /PRNewswire/ — RefluxStop™ achieves crucial FDA milestone and leaps forward with strong momentum in both the US and Europe Significant events in the third quarter of 2024 First national RefluxStop™ […]
Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval
VADUZ, Liechtenstein, Nov. 14, 2024 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment […]
